001434644 000__ 04679cam\a2200577\i\4500
001434644 001__ 1434644
001434644 003__ OCoLC
001434644 005__ 20230309003811.0
001434644 006__ m\\\\\o\\d\\\\\\\\
001434644 007__ cr\un\nnnunnun
001434644 008__ 210223s2021\\\\sz\a\\\\o\\\\\000\0\eng\d
001434644 019__ $$a1239962843$$a1241448315
001434644 020__ $$a9783030685102$$q(electronic bk.)
001434644 020__ $$a3030685101$$q(electronic bk.)
001434644 020__ $$z9783030685096
001434644 020__ $$z3030685098
001434644 0247_ $$a10.1007/978-3-030-68510-2$$2doi
001434644 035__ $$aSP(OCoLC)1241066098
001434644 040__ $$aDKU$$beng$$erda$$epn$$cDKU$$dOCLCO$$dOCLCQ$$dGW5XE$$dYDX$$dEBLCP$$dOCLCO$$dOCLCF$$dUKAHL$$dN$T$$dOCLCO$$dOCLCQ$$dOCLCO$$dCOM$$dOCLCQ
001434644 049__ $$aISEA
001434644 050_4 $$aRB170
001434644 08204 $$a616.07$$223
001434644 24500 $$aReactive oxygen species :$$bnetwork pharmacology and therapeutic applications /$$cHarald H.H.W. Schmidt, Pietro Ghezzi, Antonio Cuadrado, editors.
001434644 264_1 $$aCham :$$bSpringer,$$c[2021]
001434644 300__ $$a1 online resource (viii, 425 pages) :$$bcolor illustrations
001434644 336__ $$atext$$btxt$$2rdacontent
001434644 337__ $$acomputer$$bc$$2rdamedia
001434644 338__ $$aonline resource$$bcr$$2rdacarrier
001434644 4901_ $$aHandbook of experimental pharmacology,$$x0171-2004 ;$$vvolume 264
001434644 5050_ $$aPart I: ROS Revisited: Changing the Focus from Oxidative Stress and Redox Biology to Redox Medicine -- Demystifying oxidative stress -- Oxidants in Physiological Processes -- Network Medicine-Based Unbiased Disease Modules for Drug and Diagnostic Target Identification in ROSopathies -- Part II Targeting antioxidant responses -- Development of Telintra as an Inhibitor of Glutathione S-Transferase P -- Perspectives on the Clinical Development of NRF2-Targeting Drugs -- Part III: Inhibiting ROS formation and toxification -- NOX Inhibitors: From Bench to Naxibs to Bedside -- Nitric Oxide Synthase Inhibitors into the Clinic at Last -- Xanthine Oxidoreductase Inhibitors -- Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches -- Inhibition of Myeloperoxidase -- Part IV: Stimulating/substituting ROS -- Effects of Mammalian Thioredoxin Reductase Inhibitors -- Cardiovascular Therapeutic Potential of the Redox Siblings, Nitric Oxide (NO" and Nitroxyl (HNO), in the Setting of Reactive Oxygen Species Dysregulation -- Tetrahydrobiopterin and Nitric Oxide Synthase Recouplers -- Part V: Repairing ROS damage -- Soluble Guanylate Cyclase Stimulators and Activators -- Peter Sander -- Inhibitors of Advanced Glycation End Product (AGE) Formation and Accumulation.
001434644 506__ $$aAccess limited to authorized users.
001434644 520__ $$aReactive oxygen species (ROS) have been implicated in almost every human disease phenotype, without much, if any, therapeutic consequence foremost exemplified by the failure of the so-called anti-oxidants. This book is a game changer for the field and many clinical areas such as cardiology and neurology. The term 'oxidative stress' is abandoned and replaced with a systems medicine and network pharmacology-based mechanistic approach to disease. The ROS-related drugs discussed here target either ROS- forming or ROS -modifying enzymes for which there is strong clinical evidence. In addition, ROS targets are included as they jointly participate in causal mechanisms of disease. This approach is transforming the ROS field and represents a breakthrough in redox medicine indicating a path to patient benefit. In the coming years more targets and drugs may be discovered, but the approach will remain the same and this book will thus become, and for many years remain, the leading reference for ROSopathies and their treatment by network pharmacology. Chapter "Soluble Guanylate Cyclase Stimulators and Activators" is available open access under a Creative Commons Attribution 4.0 International License via link.springer.com
001434644 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed March 23, 2021).
001434644 650_0 $$aActive oxygen$$xPhysiological effect.
001434644 650_0 $$aOxidative stress.
001434644 650_6 $$aOxygène actif$$xEffets physiologiques.
001434644 650_6 $$aStress oxydatif.
001434644 655_0 $$aElectronic books.
001434644 7001_ $$aSchmidt, Harald H. H. W.,$$eeditor.
001434644 7001_ $$aGhezzi, P.$$q(Pietro),$$eeditor.
001434644 7001_ $$aCuadrado, Antonio,$$eeditor.
001434644 77608 $$iPrint version:$$z9783030685096
001434644 77608 $$iPrint version:$$z9783030685119
001434644 77608 $$iPrint version:$$z9783030685126
001434644 830_0 $$aHandbook of experimental pharmacology ;$$vv. 264.$$x0171-2004
001434644 852__ $$bebk
001434644 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-68510-2$$zOnline Access$$91397441.1
001434644 909CO $$ooai:library.usi.edu:1434644$$pGLOBAL_SET
001434644 980__ $$aBIB
001434644 980__ $$aEBOOK
001434644 982__ $$aEbook
001434644 983__ $$aOnline
001434644 994__ $$a92$$bISE